Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Fitting

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon Jun 30, 2021 10:17am

93 Views

Post# 33472687

RE:Fitting

kind of fitting* and Wed*. I obviously use the same proof reader as TH lol.

SABBOBCAT wrote: It is king of fitting... We'd July 15, 2021 is a day that will never come... Just like the start of the NASH Phase III... I am joking of course, but come on, release the protocol already

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec